EPO: Orphan Designation

• The FDA designated EPO as an orphan drug

  • Orphan Indication: Treatment of anemia associated with end stage renal disease.
  • Designation Date: 04/10/1986
  • Marketing Approval Date: 06/01/1989

• The orphan drug designation expired in 1996

Previous slide

Next slide

Back to first slide

View graphic version